Emerging circulating biomarkers in glioblastoma: promises and challenges

References

• Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol 2014;16(Suppl 4):iv1-63
   PubMed Web of Science ®Google Scholar
• Weller M, van den Bent M, Hopkins K, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 2014;15(9):e395-403
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10(5):459-66
   PubMed Web of Science ®Google Scholar
• Rønning PA, Helseth E, Meling TR, Johannesen TB. A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. Neuro Oncol 2012;14(9):1178-84
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127(12):2893-917
   PubMed Web of Science ®Google Scholar
• Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9(3):157-73
   PubMed Web of Science ®Google Scholar
• Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321(5897):1807-12
   PubMed Web of Science ®Google Scholar
• Network CGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061-8
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17(1):98-110
   PubMed Web of Science ®Google Scholar
• Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010;17(5):510-22
   PubMed Web of Science ®Google Scholar
• Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155(2):462-77
   PubMed Web of Science ®Google Scholar
• Frattini V, Trifonov V, Chan JM, et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 2013;45(10):1141-9
   PubMed Web of Science ®Google Scholar
• Preusser M, de Ribaupierre S, Wöhrer A, et al. Current concepts and management of glioblastoma. Ann Neurol 2011;70(1):9-21
   PubMed Web of Science ®Google Scholar
• Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol 2012;14(Suppl 4):iv100-8
   PubMed Web of Science ®Google Scholar
• Olar A, Aldape KD. Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol 2014;232(2):165-77
   PubMed Web of Science ®Google Scholar
• Prados MD, Byron SA, Tran NL, et al. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol 2015;17(8):1051-63
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352(10):997-1003
   PubMed Web of Science ®Google Scholar
• Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008;26(25):4189-99
   PubMed Web of Science ®Google Scholar
• Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27(25):4150-4
   PubMed Web of Science ®Google Scholar
• Wick W, Meisner C, Hentschel B, et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 2013;81(17):1515-22
   PubMed Web of Science ®Google Scholar
• Leary RJ, Kinde I, Diehl F, et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2010;2(20):20ra14
   PubMed Web of Science ®Google Scholar
• Leary RJ, Sausen M, Kinde I, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 2012;4(162):162ra154
   PubMed Web of Science ®Google Scholar
• Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012;4(136):136ra168
   Web of Science ®Google Scholar
• Chan KC, Jiang P, Zheng YW, et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 2013;59(1):211-24
   PubMed Web of Science ®Google Scholar
• Kristensen VN, Lingjærde OC, Russnes HG, et al. Principles and methods of integrative genomic analyses in cancer. Nat Rev Cancer 2014;14(5):299-313
   PubMed Web of Science ®Google Scholar
• Holdhoff M, Yovino SG, Boadu O, Grossman SA. Blood-based biomarkers for malignant gliomas. J Neurooncol 2013;113(3):345-52
   PubMed Web of Science ®Google Scholar
• Ilhan-Mutlu A, Wagner L, Preusser M. Circulating biomarkers of CNS tumors: an update. Biomark Med 2013;7(2):267-85
   PubMed Web of Science ®Google Scholar
• Kros JM, Mustafa DM, Dekker LJ, et al. Circulating glioma biomarkers. Neuro Oncol 2014;17(3):343-60
   PubMed Web of Science ®Google Scholar
• Best MG, Sol N, Zijl S, et al. Liquid biopsies in patients with diffuse glioma. Acta Neuropathol 2015;29(6):849-65
   Web of Science ®Google Scholar
• Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology–Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 2014;24(5):429-35
   PubMed Web of Science ®Google Scholar
• Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma. Core Evid 2012;7:93-103
   PubMedGoogle Scholar
• Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013;340(6132):626-30
   PubMed Web of Science ®Google Scholar
• Reardon DA, Wen PY, Mellinghoff IK. Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro Oncol 2014;16(Suppl 8):viii7-13
   PubMed Web of Science ®Google Scholar
• Thomas AA, Brennan CW, DeAngelis LM, Omuro AM. Emerging therapies for glioblastoma. JAMA Neurol 2014;71(11):1437-44
   PubMed Web of Science ®Google Scholar
• Gallego O, Cuatrecasas M, Benavides M, et al. Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry. J Neurooncol 2014;116(2):413-19
   PubMed Web of Science ®Google Scholar
• Di Stefano AL, Fucci A, Frattini V, et al. Detection, characterization and inhibition of FGFR-TACC fusions in IDH wild type glioma. Clin Cancer Res 2015;21(14):3307-17
   PubMed Web of Science ®Google Scholar
• Touat M, Dhermain F, André F, Sanson M. Adapting the drivers to the road: a new strategy for cancer evolution? Ann Oncol 2015;26(5):827-9
   PubMed Web of Science ®Google Scholar
• Meyer M, Reimand J, Lan X, et al. Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proc Natl Acad Sci USA 2015;112(3):851-6
   PubMed Web of Science ®Google Scholar
• Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011;20(6):810-17
   PubMed Web of Science ®Google Scholar
• Lass U, Nümann A, von Eckardstein K, et al. Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1-mutation as common tumor initiating event. PLoS One 2012;7(7):e41298
   PubMed Web of Science ®Google Scholar
• Little SE, Popov S, Jury A, et al. Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity. Cancer Res 2012;72(7):1614-20
   PubMed Web of Science ®Google Scholar
• Sottoriva A, Spiteri I, Piccirillo SG, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 2013;110(10):4009-14
   PubMed Web of Science ®Google Scholar
• Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014;343(6167):189-93
   PubMed Web of Science ®Google Scholar
• Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014;344(6190):1396-401
   PubMed Web of Science ®Google Scholar
• Francis JM, Zhang CZ, Maire CL, et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov 2014;4(8):956-71
   PubMed Web of Science ®Google Scholar
• Yap TA, Gerlinger M, Futreal PA, et al. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012;4(127):127ps110
   Web of Science ®Google Scholar
• Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013;501(7467):338-45
   PubMed Web of Science ®Google Scholar
• McGranahan N, Favero F, de Bruin EC, et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med 2015;7(283):283ra254
   Web of Science ®Google Scholar
• Lassman AB, Rossi MR, Raizer JJ, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 2005;11(21):7841-50
   PubMed Web of Science ®Google Scholar
• Nathanson DA, Gini B, Mottahedeh J, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 2014;343(6166):72-6
   PubMed Web of Science ®Google Scholar
• Group. BDW. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69(3):89-95
   PubMed Web of Science ®Google Scholar
• Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5(11):845-56
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011;11(6):426-37
   PubMed Web of Science ®Google Scholar
• Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013;10(8):472-84
   PubMed Web of Science ®Google Scholar
• Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14(9):985-90
   PubMed Web of Science ®Google Scholar
• Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368(13):1199-209
   PubMed Web of Science ®Google Scholar
• Rubin EH, Allen JD, Nowak JA, Bates SE. Developing precision medicine in a global world. Clin Cancer Res 2014;20(6):1419-27
   PubMed Web of Science ®Google Scholar
• Yabroff KR, Harlan L, Zeruto C, et al. Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006. Neuro Oncol 2012;14(3):351-9
   PubMed Web of Science ®Google Scholar
• Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009;11(1):3-14
   PubMed Web of Science ®Google Scholar
• Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28(11):1963-72
   PubMed Web of Science ®Google Scholar
• Choi C, Ganji SK, DeBerardinis RJ, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 2012;18(4):624-9
   PubMed Web of Science ®Google Scholar
• Baldock AL, Yagle K, Born DE, et al. Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status. Neuro Oncol 2014;16(6):779-86
   PubMed Web of Science ®Google Scholar
• Tykocinski ES, Grant RA, Kapoor GS, et al. Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma. Neuro Oncol 2012;14(5):613-23
   PubMed Web of Science ®Google Scholar
• Brandsma D, Stalpers L, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9(5):453-61
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Fitzner KA, Jacobs DI, et al. Economics of Malignant Gliomas: A Critical Review. J Oncol Pract 2014
   PubMedGoogle Scholar
• Schuhmann MU, Zucht HD, Nassimi R, et al. Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme. Eur J Surg Oncol 2010;36(2):201-7
   PubMed Web of Science ®Google Scholar
• Liu BL, Cheng JX, Zhang W, et al. Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. Neuro Oncol 2010;12(6):540-8
   PubMed Web of Science ®Google Scholar
• Baraniskin A, Kuhnhenn J, Schlegel U, et al. Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro Oncol 2012;14(1):29-33
   PubMed Web of Science ®Google Scholar
• Teplyuk NM, Mollenhauer B, Gabriely G, et al. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol 2012;14(6):689-700
   PubMed Web of Science ®Google Scholar
• Tumilson CA, Lea RW, Alder JE, Shaw L. Circulating microRNA biomarkers for glioma and predicting response to therapy. Mol Neurobiol 2014;50(2):545-58
   PubMed Web of Science ®Google Scholar
• Pan W, Gu W, Nagpal S, et al. Brain tumor mutations detected in cerebral spinal fluid. Clin Chem 2015;61(3):514-22
   PubMed Web of Science ®Google Scholar
• Stroun M, Lyautey J, Lederrey C, et al. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta 2001;313(1-2):139-42
   PubMed Web of Science ®Google Scholar
• Chen C, Skog J, Hsu CH, et al. Microfluidic isolation and transcriptome analysis of serum microvesicles. Lab Chip 2010;10(4):505-11
   PubMed Web of Science ®Google Scholar
• Chen WW, Balaj L, Liau LM, et al. BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. Mol Ther Nucleic Acids 2013;2:e109
   PubMedGoogle Scholar
• Redzic JS, Ung TH, Graner MW. Glioblastoma extracellular vesicles: reservoirs of potential biomarkers. Pharmgenomics Pers Med 2014;7:65-77
   PubMedGoogle Scholar
• Shao H, Chung J, Lee K, et al. Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nat Commun 2015;6:6999
   PubMed Web of Science ®Google Scholar
• Skog J, Würdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008;10(12):1470-6
   PubMed Web of Science ®Google Scholar
• Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 2008;10(5):619-24
   PubMed Web of Science ®Google Scholar
• Bronisz A, Wang Y, Nowicki MO, et al. Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1. Cancer Res 2014;74(3):738-50
   PubMed Web of Science ®Google Scholar
• Godlewski J, Krichevsky AM, Johnson MD, et al. Belonging to a network-microRNAs, extracellular vesicles, and the glioblastoma microenvironment. Neuro Oncol 2015;17(5):652-62
   PubMed Web of Science ®Google Scholar
• Noerholm M, Balaj L, Limperg T, et al. RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer 2012;12:22
   PubMed Web of Science ®Google Scholar
• Akers JC, Ramakrishnan V, Kim R, et al. MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. PLoS One 2013;8(10):e78115
   PubMed Web of Science ®Google Scholar
• Qu S, Guan J, Liu Y. Identification of microRNAs as novel biomarkers for glioma detection: a meta-analysis based on 11 articles. J Neurol Sci 2015;348(1-2):181-7
   PubMed Web of Science ®Google Scholar
• Nilsson RJ, Balaj L, Hulleman E, et al. Blood platelets contain tumor-derived RNA biomarkers. Blood 2011;118(13):3680-3
   PubMed Web of Science ®Google Scholar
• Macarthur KM, Kao GD, Chandrasekaran S, et al. Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. Cancer Res 2014;74(8):2152-9
   PubMed Web of Science ®Google Scholar
• Müller C, Holtschmidt J, Auer M, et al. Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med 2014;6(247):247ra101
   PubMed Web of Science ®Google Scholar
• Sullivan JP, Nahed BV, Madden MW, et al. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov 2014;4(11):1299-309
   PubMed Web of Science ®Google Scholar
• Krebs MG, Metcalf RL, Carter L, et al. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol 2014;11(3):129-44
   PubMed Web of Science ®Google Scholar
• Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359(4):366-77
   PubMed Web of Science ®Google Scholar
• Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008;8(5):329-40
   PubMed Web of Science ®Google Scholar
• Heitzer E, Auer M, Ulz P, et al. Circulating tumor cells and DNA as liquid biopsies. Genome Med 2013;5(8):73
   PubMedGoogle Scholar
• Baccelli I, Schneeweiss A, Riethdorf S, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013;31(6):539-44
   PubMed Web of Science ®Google Scholar
• Yu M, Bardia A, Aceto N, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014;345(6193):216-20
   PubMed Web of Science ®Google Scholar
• Yu M, Stott S, Toner M, et al. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol 2011;192(3):373-82
   PubMed Web of Science ®Google Scholar
• Alix-Panabières C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2013;59(1):110-18
   PubMed Web of Science ®Google Scholar
• Böhm C, Wassmann H, Paulus W. No evidence of tumour cells in blood of patients with glioma. Mol Pathol 2003;56(3):187-9
   PubMedGoogle Scholar
• Subramanian A, Harris A, Piggott K, et al. Metastasis to and from the central nervous system–the ’relatively protected site’. Lancet Oncol 2002;3(8):498-507
   PubMed Web of Science ®Google Scholar
• Fonkem E, Lun M, Wong ET. Rare phenomenon of extracranial metastasis of glioblastoma. J Clin Oncol 2011;29(34):4594-5
   PubMed Web of Science ®Google Scholar
• Beauchesne P. Extra-neural metastases of malignant gliomas: myth or reality? Cancers (Basel) 2011;3(1):461-77
   PubMedGoogle Scholar
• Armanios MY, Grossman SA, Yang SC, et al. Transmission of glioblastoma multiforme following bilateral lung transplantation from an affected donor: case study and review of the literature. Neuro Oncol 2004;6(3):259-63
   PubMed Web of Science ®Google Scholar
• Labussière M, Di Stefano AL, Gleize V, et al. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Br J Cancer 2014;111(10):2024-32
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6(224):224ra224
   Web of Science ®Google Scholar
• Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 2014;4(6):650-61
   PubMed Web of Science ®Google Scholar
• Boisselier B, Gállego Pérez-Larraya J, Rossetto M, et al. Detection of IDH1 mutation in the plasma of patients with glioma. Neurology 2012;79(16):1693-8
   PubMed Web of Science ®Google Scholar
• Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014;20(5):548-54
   PubMed Web of Science ®Google Scholar
• van Tellingen O, Yetkin-Arik B, de Gooijer MC, et al. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat 2015;19:1-12
   PubMed Web of Science ®Google Scholar
• Weaver KD, Grossman SA, Herman JG. Methylated tumor-specific DNA as a plasma biomarker in patients with glioma. Cancer Invest 2006;24(1):35-40
   PubMed Web of Science ®Google Scholar
• Salkeni MA, Zarzour A, Ansay TY, et al. Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients. J Neurooncol 2013;115(1):27-35
   PubMed Web of Science ®Google Scholar
• Majchrzak-Celińska A, Paluszczak J, Kleszcz R, et al. Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. J Appl Genet 2013;54(3):335-44
   PubMed Web of Science ®Google Scholar
• Balaña C, Ramirez JL, Taron M, et al. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 2003;9(4):1461-8
   PubMed Web of Science ®Google Scholar
• Wakabayashi T, Natsume A, Hatano H, et al. p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas. Neurosurgery 2009;64(3):455-61; discussion 461-452
   PubMed Web of Science ®Google Scholar
• Lavon I, Refael M, Zelikovitch B, et al. Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro Oncol 2010;12(2):173-80
   PubMed Web of Science ®Google Scholar
• Piccioni DE, Lanman RB, Nagy RJ, et al. Analysis of cell-free circulating tumor DNA in patients with glioblastoma and other primary brain tumors. J Clin Oncol 2015
   Google Scholar
• Fiano V, Trevisan M, Trevisan E, et al. MGMT promoter methylation in plasma of glioma patients receiving temozolomide. J Neurooncol 2014;117(2):347-57
   PubMed Web of Science ®Google Scholar
• Balańa C, Carrato C, Ramírez JL, et al. Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients. Clin Transl Oncol 2011;13(9):677-85
   PubMed Web of Science ®Google Scholar
• Møller HG, Rasmussen AP, Andersen HH, et al. A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion. Mol Neurobiol 2013;47(1):131-44
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116(2):281-97
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6(4):259-69
   PubMed Web of Science ®Google Scholar
• Roth P, Wischhusen J, Happold C, et al. A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem 2011;118(3):449-57
   PubMed Web of Science ®Google Scholar
• Ilhan-Mutlu A, Wagner L, Wöhrer A, et al. Plasma MicroRNA-21 concentration may be a useful biomarker in glioblastoma patients. Cancer Invest 2012;30(8):615-21
   PubMed Web of Science ®Google Scholar
• Ma R, Zhang G, Wang H, et al. Downregulation of miR-544 in tissue, but not in serum, is a novel biomarker of malignant transformation in glioma. Oncol Lett 2012;4(6):1321-4
   PubMed Web of Science ®Google Scholar
• Wang Q, Li P, Li A, et al. Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J Exp Clin Cancer Res 2012;31:97
   PubMed Web of Science ®Google Scholar
• Yang C, Wang C, Chen X, et al. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer 2013;132(1):116-27
   PubMed Web of Science ®Google Scholar
• Zhi F, Shao N, Wang R, et al. Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma. Neuro Oncol 2014;17(3):383-91
   PubMed Web of Science ®Google Scholar
• Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18(10):997-1006
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360(8):765-73
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 2014;32(8):783-90
   PubMed Web of Science ®Google Scholar
• Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010;75(17):1560-6
   PubMed Web of Science ®Google Scholar
• Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov 2013;3(7):730-41
   PubMed Web of Science ®Google Scholar
• Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012;483(7390):479-83
   PubMed Web of Science ®Google Scholar
• Janin M, Mylonas E, Saada V, et al. Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol 2014;32(4):297-305
   PubMed Web of Science ®Google Scholar
• Borger DR, Goyal L, Yau T, et al. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res 2014;20(7):1884-90
   PubMed Web of Science ®Google Scholar
• Fathi AT, Sadrzadeh H, Borger DR, et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood 2012;120(23):4649-52
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Propert KJ, Loren AW, et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood 2013;121(24):4917-24
   PubMed Web of Science ®Google Scholar
• Capper D, Simon M, Langhans CD, et al. 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int J Cancer 2012;131(3):766-8
   PubMed Web of Science ®Google Scholar
• Lombardi G, Corona G, Bellu L, et al. Diagnostic Value of Plasma and Urinary 2-Hydroxyglutarate to Identify Patients With Isocitrate Dehydrogenase-Mutated Glioma. Oncologist 2015;20(5):562-7
   PubMed Web of Science ®Google Scholar
• Rosengren LE, Lycke J, Andersen O. Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit. J Neurol Sci 1995;133(1-2):61-5
   PubMed Web of Science ®Google Scholar
• Aurell A, Rosengren LE, Karlsson B, et al. Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction. Stroke 1991;22(10):1254-8
   PubMed Web of Science ®Google Scholar
• Herrmann M, Ehrenreich H. Brain derived proteins as markers of acute stroke: their relation to pathophysiology, outcome prediction and neuroprotective drug monitoring. Restor Neurol Neurosci 2003;21(3-4):177-90
   PubMed Web of Science ®Google Scholar
• Pelinka LE, Kroepfl A, Schmidhammer R, et al. Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. J Trauma 2004;57(5):1006-12
   PubMed Web of Science ®Google Scholar
• Foerch C, Curdt I, Yan B, et al. Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J Neurol Neurosurg Psychiatry 2006;77(2):181-4
   PubMed Web of Science ®Google Scholar
• Jung CS, Foerch C, Schänzer A, et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 2007;130(Pt 12):3336-41
   PubMed Web of Science ®Google Scholar
• Brommeland T, Rosengren L, Fridlund S, et al. Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas. Acta Neurol Scand 2007;116(6):380-4
   PubMed Web of Science ®Google Scholar
• Lyubimova NV, Toms MG, Popova EE, et al. Neurospecific proteins in the serum of patients with brain tumors. Bull Exp Biol Med 2011;150(6):732-4
   PubMed Web of Science ®Google Scholar
• Husain H, Savage W, Grossman SA, et al. Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas. J Neurooncol 2012;109(1):123-7
   PubMed Web of Science ®Google Scholar
• Ilhan-Mutlu A, Wagner L, Widhalm G, et al. Exploratory investigation of eight circulating plasma markers in brain tumor patients. Neurosurg Rev 2013;36(1):45-55; discussion 55-46
   PubMed Web of Science ®Google Scholar
• Todaro L, Christiansen S, Varela M, et al. Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors. J Neurooncol 2007;83(2):135-44
   PubMed Web of Science ®Google Scholar
• Kanner AA, Marchi N, Fazio V, et al. Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions. Cancer 2003;97(11):2806-13
   PubMed Web of Science ®Google Scholar
• Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 2002;62(15):4364-8
   PubMed Web of Science ®Google Scholar
• Hormigo A, Gu B, Karimi S, et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 2006;12(19):5698-704
   PubMed Web of Science ®Google Scholar
• Bernardi D, Padoan A, Ballin A, et al. Serum YKL-40 following resection for cerebral glioblastoma. J Neurooncol 2012;107(2):299-305
   PubMed Web of Science ®Google Scholar
• Iwamoto FM, Hottinger AF, Karimi S, et al. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol 2011;13(11):1244-51
   PubMed Web of Science ®Google Scholar
• Friedberg MH, Glantz MJ, Klempner MS, et al. Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer 1998;82(5):923-30
   PubMed Web of Science ®Google Scholar
• Pagenstecher A, Wussler EM, Opdenakker G, et al. Distinct expression patterns and levels of enzymatic activity of matrix metalloproteinases and their inhibitors in primary brain tumors. J Neuropathol Exp Neurol 2001;60(6):598-612
   PubMed Web of Science ®Google Scholar
• Komatsu K, Nakanishi Y, Nemoto N, et al. Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas. Brain Tumor Pathol 2004;21(3):105-12
   PubMedGoogle Scholar
• Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11(1):83-95
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Duda DG, di Tomaso E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010;28(17):2817-23
   PubMed Web of Science ®Google Scholar
• Tabouret E, Boudouresque F, Barrie M, et al. Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro Oncol 2014;16(3):392-9
   PubMed Web of Science ®Google Scholar
• de Groot JF, Piao Y, Tran H, et al. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res 2011;17(14):4872-81
   PubMed Web of Science ®Google Scholar
• Gerstner ER, Eichler AF, Plotkin SR, et al. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol 2011;103(2):325-32
   PubMed Web of Science ®Google Scholar
• Crocker M, Ashley S, Giddings I, et al. Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor. Neuro Oncol 2011;13(1):99-108
   PubMed Web of Science ®Google Scholar
• Lin Y, Wang JF, Gao GZ, et al. Plasma levels of tissue inhibitor of matrix metalloproteinase-1 correlate with diagnosis and prognosis of glioma patients. Chin Med J (Engl) 2013;126(22):4295-300
   PubMed Web of Science ®Google Scholar
• Sreekanthreddy P, Srinivasan H, Kumar DM, et al. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev 2010;19(6):1409-22
   PubMed Web of Science ®Google Scholar
• Güttler A, Giebler M, Cuno P, et al. Osteopontin and splice variant expression level in human malignant glioma: radiobiologic effects and prognosis after radiotherapy. Radiother Oncol 2013;108(3):535-40
   PubMed Web of Science ®Google Scholar
• Groves MD, Puduvalli VK, Chang SM, et al. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 2007;81(3):271-7
   PubMed Web of Science ®Google Scholar
• Kesari S, Schiff D, Henson JW, et al. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol 2008;10(3):300-8
   PubMed Web of Science ®Google Scholar
• Ilhan A, Gartner W, Neziri D, et al. Angiogenic factors in plasma of brain tumour patients. Anticancer Res 2009;29(2):731-6
   PubMed Web of Science ®Google Scholar
• Rafat N, Beck GCh, Schulte J, et al. Circulating endothelial progenitor cells in malignant gliomas. J Neurosurg 2010;112(1):43-9
   PubMed Web of Science ®Google Scholar
• Carlsson A, Persson O, Ingvarsson J, et al. Plasma proteome profiling reveals biomarker patterns associated with prognosis and therapy selection in glioblastoma multiforme patients. Proteomics Clin Appl 2010;4(6-7):591-602
   PubMed Web of Science ®Google Scholar
• Reynés G, Vila V, Martín M, et al. Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neurooncol 2011;102(1):35-41
   PubMed Web of Science ®Google Scholar
• Corsini E, Ciusani E, Gaviani P, et al. Decrease in circulating endothelial progenitor cells in treated glioma patients. J Neurooncol 2012;108(1):123-9
   PubMed Web of Science ®Google Scholar
• Albulescu R, Codrici E, Popescu ID, et al. Cytokine patterns in brain tumour progression. Mediators Inflamm 2013;2013:979748
   PubMed Web of Science ®Google Scholar
• Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000;18(4):708-15
   PubMed Web of Science ®Google Scholar
• Chinnaiyan P, Chowdhary S, Potthast L, et al. Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma. Neuro Oncol 2012;14(1):93-100
   PubMed Web of Science ®Google Scholar
• Quaranta M, Divella R, Daniele A, et al. Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas. Tumori 2007;93(3):275-80
   PubMed Web of Science ®Google Scholar
• Schneider T, Sailer M, Ansorge S, et al. Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma. J Neurooncol 2006;79(1):61-5
   PubMed Web of Science ®Google Scholar